TOKYO, Japan & BASKING RIDGE, NJ, USA I January 17, 2055 I DATROWAY® (datopotamab deruxtecan-dlnk) has been approved in the U.S. for the treatment of ...
with a forecast of 5.2% annual sales growth through 2028 as newer treatments offset patent losses. What strategies should investors consider when investing in this burgeoning industry? Our latest ...